 |
SINGAPORE, May 7, 2025 /PRNewswire/ -- GRVT (pronounced "gravity"), the world's first licensed onchain exchange - is excited to announce its largest trading competition to date, running from May 7 to June 5, 2025. The competition offers retail traders the chance to win a share of up to 175,000 USDT and 85 million Trader Points.
The event is open to all KYC-verified GRVT users and features a volume-based rewards system with nine reward bands and 15 prize levels. Participants will be rewarded based on their total trading volume during the competition period. The total reward pool will expand as the overall trading volume increases.
Early participants can also take advantage of special bonus rewards, and lucky traders will receive exclusive GRVT-branded merchandise.
Hong Yea, co-founder and CEO of GRVT, commented, "This trading competition marks the biggest event for our retail traders since our Mainnet launch at the end of last year. I am incredibly proud of what the team has delivered since Mainnet, and I'm grateful for the enthusiasm and support from our global community. We are committed to continuous improvement and look forward to bringing even more exciting opportunities to our users."
For full details about the GRVT Trading Competition, including the complete rules and reward structure, please visit: https://help.grvt.io/en/articles/11168184-grvt-trading-rush
Disclaimer: Perpetuals trading of cryptocurrencies is subject to high market risk and price volatility and you may be called upon at short notice to commit further margin deposits or risk being liquidated. This content is not a distribution of, or an offer or solicitation to provide, financial services or products, nor a representation as to their suitability or legality for you. GRVT is not a regulated entity and your funds are not subject to regulatory protection. Before making any decision based on this content, please seek financial and legal advice, and carefully review our Risk Disclosure and Disclaimer in full.
Singapore users: GRVT is not licensed, approved, authorised, designated, recognised, registered or otherwise regulated under any legislation administered by the Monetary Authority of Singapore ("MAS"). As such, users will not have the benefit of any regulatory safeguards imposed by the MAS.
About GRVT
GRVT (pronounced "gravity") is a blockchain-based platform that is democratizing how wealth is created and shared. It allows everyday people to trade, invest, and grow their wealth by providing direct access to top industry traders and investors. As the world's first licensed onchaindecentralized exchange, GRVT is where traditional banking meets decentralized innovation on one regulated, compliant, trustless financial market place.
GRVT official website: https://grvt.io/
For media inquiries, contact: press@grvt.io
Social and Community: X | LinkedIn | Telegram | Discord
SINGAPORE, May 7, 2025 /PRNewswire/ -- GRVT (pronounced "gravity"), the world's first licensed onchain exchange - is excited to announce its largest trading competition to date, running from May 7 to June 5, 2025. The competition offers retail traders the chance to win a share of up to 175,000 USDT and 85 million Trader Points.
The event is open to all KYC-verified GRVT users and features a volume-based rewards system with nine reward bands and 15 prize levels. Participants will be rewarded based on their total trading volume during the competition period. The total reward pool will expand as the overall trading volume increases.
Early participants can also take advantage of special bonus rewards, and lucky traders will receive exclusive GRVT-branded merchandise.
Hong Yea, co-founder and CEO of GRVT, commented, "This trading competition marks the biggest event for our retail traders since our Mainnet launch at the end of last year. I am incredibly proud of what the team has delivered since Mainnet, and I'm grateful for the enthusiasm and support from our global community. We are committed to continuous improvement and look forward to bringing even more exciting opportunities to our users."
For full details about the GRVT Trading Competition, including the complete rules and reward structure, please visit: https://help.grvt.io/en/articles/11168184-grvt-trading-rush
Disclaimer: Perpetuals trading of cryptocurrencies is subject to high market risk and price volatility and you may be called upon at short notice to commit further margin deposits or risk being liquidated. This content is not a distribution of, or an offer or solicitation to provide, financial services or products, nor a representation as to their suitability or legality for you. GRVT is not a regulated entity and your funds are not subject to regulatory protection. Before making any decision based on this content, please seek financial and legal advice, and carefully review our Risk Disclosure and Disclaimer in full.
Singapore users: GRVT is not licensed, approved, authorised, designated, recognised, registered or otherwise regulated under any legislation administered by the Monetary Authority of Singapore ("MAS"). As such, users will not have the benefit of any regulatory safeguards imposed by the MAS.
About GRVT
GRVT (pronounced "gravity") is a blockchain-based platform that is democratizing how wealth is created and shared. It allows everyday people to trade, invest, and grow their wealth by providing direct access to top industry traders and investors. As the world's first licensed onchaindecentralized exchange, GRVT is where traditional banking meets decentralized innovation on one regulated, compliant, trustless financial market place.
GRVT official website: https://grvt.io/
For media inquiries, contact: press@grvt.io
Social and Community: X | LinkedIn | Telegram | Discord
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
GRVT Launches Biggest Ever Trading Competition for Retail Traders, Offering Up to 175,000 USDT in Prizes
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
